Ravulizumab Injection Suppliers & Bulk Manufacturers
Available Forms: Concentrate vial (IV infusion)
Available Strengths: 300 mg/3 mL, 1100 mg/11 mL (100 mg/mL)
Pack Sizes: Single vial
Originator reference: Ultomiris (AstraZeneca / Alexion) (brand names belong to their owners and are shown only to identify the originator medicine)
Category: Orphan Drugs
Ravulizumab (Ultomiris, AstraZeneca/Alexion) is a long-acting complement C5 inhibitor for PNH, atypical HUS, generalised myasthenia gravis and NMOSD. Maintenance infusions are given every eight weeks instead of every two weeks with eculizumab. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.
Manufacture or export Ravulizumab Injection? List it or send an offer →
Product Description:
Ravulizumab is a monoclonal antibody that blocks complement protein C5, stopping the formation of the membrane attack complex that destroys red blood cells in paroxysmal nocturnal haemoglobinuria (PNH) and damages blood vessels, nerves and muscle junctions in other complement-driven diseases. It was engineered from eculizumab to stay in the body about four times longer.
It is approved for PNH, atypical haemolytic uraemic syndrome (aHUS), anti-acetylcholine-receptor-positive generalised myasthenia gravis and AQP4-positive neuromyelitis optica spectrum disorder (NMOSD). After a weight-based loading dose, maintenance infusions are given every eight weeks. As with all C5 inhibitors, patients must be vaccinated against meningococcal infection before starting.
Sourcing notes. Ravulizumab is patented and there is no biosimilar, while eculizumab biosimilars are already available in several markets. Orders are weight-based and high value, so we confirm the vial mix and cold-chain plan before quoting. Eculizumab and its biosimilars are also listed on PharmaTradz.
How Ravulizumab Injection is supplied today, and licensing ahead of patent expiry
Frequently Asked Questions
PNH, atypical HUS, generalised myasthenia gravis and NMOSD.
Ultomiris, from AstraZeneca (Alexion).
It blocks the same target, C5, but lasts longer, so maintenance infusions are every eight weeks instead of every two weeks.
No. It is patented. We handle authorised-supply enquiries and connect developers and licensees preparing for patent expiry.
Related Products
Elexacaftor + Tezacaftor + Ivacaftor Tablets
Strength:
100 mg/50 mg/75 mg + ivacaftor 150 mg; 50/25/37.5 mg + ivacaftor 75 mg; granules for children
Form: Film-coated tablets, oral granules
Originator reference: Trikafta (US), Kaftrio (EU) (Vertex)
View DetailsVosoritide for Injection
Strength:
0.4 mg, 0.56 mg, 1.2 mg
Form: Lyophilised powder vial (subcutaneous)
Originator reference: Voxzogo (BioMarin)
View DetailsCopper Histidinate Injection
Strength:
250 mcg copper (as copper histidinate) per dose
Form: Subcutaneous injection
Originator reference: Zycubo
View DetailsPegzilarginase Injection
Strength:
5 mg/mL (2 mg/0.4 mL vial)
Form: Solution vial (IV or subcutaneous)
Originator reference: Loargys
View DetailsTaliglucerase Alfa
Strength:
200U
Form: Injection
Originator reference: Elelyso (USA/EU)
View DetailsAgalsidase Beta
Strength:
35 mg
Form: Injection
Originator reference: Fabrazyme (USA/EU)
View DetailsMigalastat Hydrochloride
Strength:
123 mg
Form: Capsules
Originator reference: Galafold (USA/EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit